These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 7199742)

  • 41. Reduced expression of haloperidol conditioned catalepsy in rats by the dopamine D3 receptor antagonists nafadotride and NGB 2904.
    Banasikowski TJ; Beninger RJ
    Eur Neuropsychopharmacol; 2012 Oct; 22(10):761-8. PubMed ID: 22410316
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Biphasic dose-response effect of baclofen on haloperidol catalepsy in the rat.
    Richardson JS; Richardson AK
    Pharmacol Biochem Behav; 1982 Oct; 17(4):855-6. PubMed ID: 6891066
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [The influence of calcium channel blockers on the effects of haloperidol and phenamine in mice and rats].
    Kozlovskiĭ VL; Prakh'e IV; Kenunen OG
    Eksp Klin Farmakol; 1996; 59(3):12-5. PubMed ID: 8974575
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The dopamine D2 antagonist remoxipride acts in vivo on a subpopulation of dopamine D2 receptors.
    Ogren SO; Rosén L; Fuxe K
    Neuroscience; 1994 Jul; 61(2):269-83. PubMed ID: 7969908
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Striatal and nucleus accumbens D1/D2 dopamine receptors in neuroleptic catalepsy.
    Ossowska K; Karcz M; Wardas J; Wolfarth S
    Eur J Pharmacol; 1990 Jul; 182(2):327-34. PubMed ID: 1975782
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Nicotine potentiates the behavioral effects of haloperidol.
    Emerich DF; Norman AB; Sanberg PR
    Psychopharmacol Bull; 1991; 27(3):385-90. PubMed ID: 1775613
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Haloperidol conditioned catalepsy in rats: a possible role for D1-like receptors.
    Banasikowski TJ; Beninger RJ
    Int J Neuropsychopharmacol; 2012 Nov; 15(10):1525-34. PubMed ID: 22093169
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The effect of antihistaminics on cataleptogenic action of analgesics and haloperidol.
    Malec D; Langwiński R
    Pol J Pharmacol Pharm; 1983; 35(4):293-300. PubMed ID: 6141553
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties.
    Janssen PA; Niemegeers CJ; Awouters F; Schellekens KH; Megens AA; Meert TF
    J Pharmacol Exp Ther; 1988 Feb; 244(2):685-93. PubMed ID: 2450200
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hypokinesia in mice and catalepsy in rats elicited by morphine associated with antidopaminergic agents, including atypical neuroleptics.
    Barghon R; Protais P; Colboc O; Costentin J
    Neurosci Lett; 1981 Nov; 27(1):69-73. PubMed ID: 6120489
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Possible dissociation of central dopamine receptor antagonism and cataleptic behavior.
    Hruska RE
    Pharmacol Biochem Behav; 1985 Nov; 23(5):789-95. PubMed ID: 4080765
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Differential liabilities of haloperidol and thioridazine for inducing apomorphine hypersensitivity.
    De Veaugh-Geiss J; Devanand DP; Carey RJ
    Biol Psychiatry; 1982 Nov; 17(11):1289-301. PubMed ID: 6891268
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Circadian changes in behavioral effects of haloperidol in rats.
    Campbell A; Baldessarini RJ
    Psychopharmacology (Berl); 1982; 77(2):150-5. PubMed ID: 6812132
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Streptozotocin-induced diabetes differentially modifies haloperidol- and gamma-hydroxybutyric acid (GHB)-induced catalepsy.
    Sevak RJ; Koek W; France CP
    Eur J Pharmacol; 2005 Jul; 517(1-2):64-7. PubMed ID: 15975572
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of L-dopa and bromocriptine on haloperidol-induced motor deficits in mice.
    Kobayashi T; Araki T; Itoyama Y; Takeshita M; Ohta T; Oshima Y
    Life Sci; 1997; 61(26):2529-38. PubMed ID: 9416775
    [TBL] [Abstract][Full Text] [Related]  

  • 56. In vitro and in vivo pharmacological profile of 4-(4-fluorobenzylidene)-1-[2-[5-(4-fluorophenyl)-1H-pyrazol-4-yl] ethyl] piperidine (NRA0161).
    Suzuki Y; Funakoshi T; Chaki S; Kawashima N; Ogawa S; Kumagai T; Nakazato A; Komurasaki T; Okuyama S
    Life Sci; 2002 Oct; 71(22):2603-15. PubMed ID: 12354579
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tolerance of haloperidol catalepsy.
    Ezrin-Waters C; Seeman P
    Eur J Pharmacol; 1977 Feb; 41(3):321-7. PubMed ID: 556989
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Relative importance of the dopaminergic system in haloperidol-catalepsy and the anticataleptic effect of antidepressants and methamphetamine in rats.
    Al-Khatib IM; Fujiwara M; Ueki S
    Pharmacol Biochem Behav; 1989 May; 33(1):93-7. PubMed ID: 2528750
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Selective D2 dopamine receptor agonists prevent catalepsy induced by SCH 23390, a selective D1 antagonist.
    Meller E; Kuga S; Friedhoff AJ; Goldstein M
    Life Sci; 1985 May; 36(19):1857-64. PubMed ID: 3157851
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Serotonergic involvement in haloperidol-induced catalepsy.
    Neal-Beliveau BS; Joyce JN; Lucki I
    J Pharmacol Exp Ther; 1993 Apr; 265(1):207-17. PubMed ID: 8386235
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.